# Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

> **NCT06580106** · — · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **OTHER:** Biospecimen samples

## Key facts

- **NCT ID:** NCT06580106
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-07
- **Final completion:** 2030-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580106, "Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06580106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*